Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Sangamo Therapeutics to post earnings of ($0.12) per share and revenue of $7.90 million for the quarter.
Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The business had revenue of $7.55 million during the quarter, compared to analyst estimates of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, analysts expect Sangamo Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Sangamo Therapeutics Price Performance
Sangamo Therapeutics stock traded down $0.03 during mid-day trading on Tuesday, hitting $0.69. 965,569 shares of the company were exchanged, compared to its average volume of 8,532,173. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The company has a market capitalization of $157.46 million, a P/E ratio of -0.91 and a beta of 1.46. The business's 50 day simple moving average is $0.80 and its two-hundred day simple moving average is $1.38.
Analyst Ratings Changes
Several research analysts recently weighed in on SGMO shares. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Finally, Truist Financial decreased their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.17.
Check Out Our Latest Stock Analysis on SGMO
Sangamo Therapeutics Company Profile
(
Get Free Report)
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Further Reading
Before you consider Sangamo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.
While Sangamo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
